News
USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...
On its clinic website, the supermarket chain said the self-injectable pens can be used once a week to increase a user’s ...
4d
MedPage Today on MSNShock Wave Therapy for Post-Prostatectomy Erectile Dysfunction No Better Than ShamPostoperative penile hypoxia is one potential contributor, Pedersen and co-authors noted. The rationale for LI-SWT to treat ...
Read the full paper here. The post Study finds erectile dysfunction for 1 in 5 men even years after Covid infection appeared first on Boing Boing.
A new study conducted on medical students found that those who suffer from Irritable Bowel Syndrome are 108 percent more likely to develop erectile dysfunction.
A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The ...
Of 609 men surveyed, 19% continued to have erectile dysfunction after being hospitalized with COVID-19. Nearly half still had ED after two years.
The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in deaths, cardiovascular disease, and dementia ...
In the US alone approximately 30 million men are living with erectile dysfunction while an estimated 2 out of every 100 American males is not producing testosterone within a typical healthy range ...
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).
A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...
New research highlights that 65.8% of diabetic men suffer from erectile dysfunction. Early detection and better diabetes control are key to reducing this common yet serious condition.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results